What predicts minimal response to abiraterone in metastatic castrate resistant prostate cancer?

被引：0
|
作者：
Davies, Rhian Sian
Smith, Christian
Frazer, Ricky Dylan
Button, Mick
Tanguay, Jacob
Barber, Jim
Palaniappan, Nachi
Staffurth, John
Lester, Jason Francis
机构：
[1] Velindre Canc Ctr, Cardiff, S Glam, Wales
[2] Singleton Hosp, Barry, Wales
[3] Velindre Hosp, Cardiff, S Glam, Wales
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.e16103
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16103
引用
收藏
页数：1
相关论文
共 50 条
  • [1] What Predicts Minimal Response to Abiraterone in Metastatic Castrate-resistant Prostate Cancer?
    Davies, Rhian Sian
    Smith, Christian
    Button, Michael Robert
    Tanguay, Jacob
    Barber, Jim
    Palaniappan, Nachiappan
    Staffurth, John
    Lester, Jason Francis
    [J]. ANTICANCER RESEARCH, 2015, 35 (10) : 5615 - 5621
  • [2] Abiraterone for the Treatment of Metastatic Castrate-Resistant Prostate Cancer
    Beckett, Robert D.
    Rodeffer, Kathryn M.
    Snodgrass, Rachel
    [J]. ANNALS OF PHARMACOTHERAPY, 2012, 46 (7-8) : 1016 - 1024
  • [3] Pragmatic predictors of response to abiraterone in metastatic castrate resistant-prostate cancer.
    Davies, Rhian Sian
    Lester, Jason Francis
    Smith, Christian
    Casbard, Angela Claire
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [4] Retreatment of Men With Metastatic Castrate-Resistant Prostate Cancer With Abiraterone
    Leibowitz-Amit, Raya
    Alimohamed, Nimira
    Vera-Badillo, Francisco E.
    Seah, Jo-An
    Templeton, Arnoud J.
    Knox, Jennifer J.
    Tannock, Ian F.
    Sridhar, Srikala S.
    Joshua, Anthony M.
    [J]. PROSTATE, 2014, 74 (14): : 1462 - 1464
  • [5] Abiraterone in heavily pretreated patients with metastatic castrate-resistant prostate cancer
    Francini, Edoardo
    Fiaschi, Anna Ida
    Petrioli, Roberto
    Francini, Filippo
    Bianco, Vincenzo
    Perrella, Armando
    Paganini, Giovanni
    Laera, Letizia
    Roviello, Giandomenico
    [J]. ANTI-CANCER DRUGS, 2014, 25 (04) : 472 - 477
  • [6] Enzalutamide after abiraterone in patients with metastatic castrate-resistant prostate cancer (mCRPC).
    Sandhu, Gurprataap Singh
    Parikh, Rahul Atul
    Appleman, Leonard Joseph
    Friedland, David
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [7] PHARMACOECONOMIC ANALYSIS OF ABIRATERONE USED FOR METASTATIC CASTRATE -RESISTANT PROSTATE CANCER BEFORE CHEMOTHERAPY
    Avxentyev, N.
    Derkach, E., V
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A730 - A730
  • [8] Reply to: Enzalutamide after failure of docetaxel and abiraterone in metastatic castrate resistant prostate cancer
    Lorente, David
    Bianchini, Diletta
    Rodriguez-Vida, Alejo
    Omlin, Aurelius
    Pezaro, Carmel
    Ferraldeschi, Roberta
    Zivi, Andrea
    Attard, Gerhardt
    Chowdhury, Simon
    De Bono, Johann S.
    [J]. EUROPEAN JOURNAL OF CANCER, 2014, 50 (05) : 1042 - 1043
  • [9] Enzalutamide after failure of docetaxel and abiraterone in metastatic castrate-resistant prostate cancer
    Thomson, David
    Charnley, Natalie
    Parikh, Omi
    [J]. EUROPEAN JOURNAL OF CANCER, 2014, 50 (05) : 1040 - 1041
  • [10] PSA response in black and white patients treated with abiraterone acetate (AA) for metastatic castrate resistant prostate cancer (mCRPC).
    Ramalingam, Sundhar
    Humeniuk, Michael Sandon
    Hu, Rachel
    Rasmussen, Julia
    Healy, Patrick
    Wu, Yuan
    Harrison, Michael Roger
    Armstrong, Andrew J.
    George, Daniel J.
    Zhang, Tian
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345